Bibliography
- Siest G , BastienB, BenachourH et al.: From human genetic variations to prediction of risks and responses to drugs and the environment.Per. Med.4 , 95–104 (2007).
- Siest G , BenachourH, LambertD et al.: Functional genomics towards personalized healthcare.Per. Med.6 , 19–32 (2009).
- Gurwitz D , LunshofJE, DedoussisG et al.: Pharmacogenomics education: international society of pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.Pharmacogenomics J.5 , 221–225 (2005).
- Koster ES , Maitland-van der Zee AH, Rodin AS, Raaijmakers JAM: Systems biology in pharmacogenomic research: the way to personalized prescribing? Pharmacogenomics10(6) , 971–981 (2009).
- Winkelmann BR : The cardiovascular genomics revolution – where is the clinical benefit?Clin. Chem. Lab. Med.46 , A107 (2008) (Abstract).
- Becquemont L : Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Pharmacogenomics10(6) , 961–969 (2009).
- Cooper GM , JohnsonJA, LangaeeTY et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.Blood112 , 1022–1027 (2008).
- Borgiani P , CiccacciC, ForteV et al.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.Pharmacogenomics10 , 261–266 (2009).
- The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359 , 789–799 (2008).
- Martin ER , LaiEH, GilbertJR et al.: SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.Am. J. Hum. Genet.67 , 383–394 (2000).
- Gomez A , Ingelman-SundbergM: Epigenetic and microRNA dependent control of cytochrome P450 expression: a gap between DNA and protein.Pharmacogenomics (2009) 10.2217/PGS.09.56 (In press).
- Johnson AD , ZhangY, PappAC et al.: Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.Pharmacogenet. Genomics18 , 781–791 (2008).
- Jeannesson E , SiestG, ZaiouM, BerrahmouneH, MassonC, Visvikis-SiestS: Genetic profiling of human cell lines used as in vitro model to study cardiovascular physiopathology and pharmacotoxicology.Cell. Biol. Toxicol. (2009) (Epub ahead of print).
- Arrell DK , NiederlanderNJ, Perez-TerzicC, ChungS, BehfarA, TerzicA: Pharmacoproteomics: advancing the efficacy and safety of regenerative therapeutics.Clin. Pharmacol. Ther.82 , 316–319 (2007).
- Shiota M , KusakabeH, HikitaY, NakaoT, IzumiY, IwaoH: Pharmacogenomics of cardiovascular pharmacology: molecular network analysis in pleiotropic effects of statin – an experimental elucidation of the pharmacologic action from protein-protein interaction analysis.J. Pharmacol. Sci.107 , 15–19 (2008).
- Arvanitidis K , RagiaG, TavridouA, ManolopoulosVG: The prevalence of the novel CYP2C19*17 allele variant in the Greek population.Clin. Chem. Lab. Med.46 , A137 (2008) (Abstract).
- Kim KA , ParkPW, ParkJY: Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects.Eur. J. Clin Pharmacol.64 , 589–597 (2008).
- Peñas-LLedó EM , DoradoP, PachecoR, GonzálezI, LLerenaA: Relation between CYP2D6 genotype personality, neurocognition and overall psychopathology in healthy volunteers.Pharmacogenomics (2009) 10.2217/PGS.09.75 (In press).
- Ingelman-Sundberg M , SimSC, GomezA, Rodriguez-AntonaC: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.Pharmacol. Ther.116 , 496–526 (2007).
- Kirchheiner J : Sex-specific differences in side effects of psychotropic drugs – genes or gender?Pharmacogenomics (2009) (In press).
- Frueh FW , AmurS, MummanneniP et al.: Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use.Pharmacotherapy28 , 992–998 (2008).
- Frueh FW : Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine.Pharmacogenomics (2009) 10.2217/PGS.09.62 (In press).
- Lacana E , AmurS, MummanneniP, ZhaoH, FruehFW: The emerging role of pharmacogenomics in biologics.Clin. Pharmacol. Ther.82 , 466–471 (2007).
- Owen RP , KleinTE, AltmanRB: The education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB).Clin. Pharmacol. Ther.82 , 472–475 (2007).
- Tchelet A : The Industry Pharmacogenomics Working Group: current activities.Clin. Chem. Lab. Med.46 , A120 (2008) (Abstract).
- Crowley JJ , SullivanPF, McLeodHL: Pharmacogenomic genome-wide association studies: lessons learned thus far.Pharmacogenomics10 , 161–163 (2009).
- Siest G , JeannessonE, MarteauJB et al.: Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects.Drug Metab. Dispos.36 , 182–189 (2008).
- Siest G , MarteauJB, MaumusS et al.: Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers.Eur. J. Pharmacol.527 , 1–22 (2005).